Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Cancer

Retrieve available abstracts of 85 articles:
HTML format

Single Articles

    July 2021
  1. HU B, Boselli D, Pye LM, Chen T, et al
    Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma.
    Cancer. 2021 Jul 21. doi: 10.1002/cncr.33779.
    PubMed     Abstract available

  2. JUWEID ME, Mueller M, Alhouri A, A-Risheq MZ, et al
    Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Cancer. 2021 Jul 19. doi: 10.1002/cncr.33772.
    PubMed     Abstract available

    June 2021
  3. EL-GALALY TC, Ovlisen AK, Cheah CY
    Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors?
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33659.

  4. GOLDMAN ML, Mao JJ, Strouse CS, Chen W, et al
    Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33660.
    PubMed     Abstract available

    October 2020
  5. BORTHAKUR G, Martinelli G, Raffoux E, Chevallier P, et al
    Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Cancer. 2020 Oct 27. doi: 10.1002/cncr.33188.
    PubMed     Abstract available

    August 2020
  6. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016).
    Cancer. 2020 Aug 7. doi: 10.1002/cncr.33117.
    PubMed     Abstract available

    June 2020
  7. KARSCHNIA P, Batchelor TT, Jordan JT, Shaw B, et al
    Primary dural lymphomas: Clinical presentation, management, and outcome.
    Cancer. 2020;126:2811-2820.
    PubMed     Abstract available

  8. BLESSING AM, Santiago-O'Farrill JM, Mao W, Pang L, et al
    Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32985.
    PubMed     Abstract available

    May 2020
  9. LEE MJ, Koff JL, Switchenko JM, Jhaney CI, et al
    Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-Cell lymphoma.
    Cancer. 2020 May 29. doi: 10.1002/cncr.32866.
    PubMed     Abstract available

    February 2020
  10. JAGADEESH D, Majhail NS, He Y, Ahn KW, et al
    Outcomes of Rituximab-BEAM Versus BEAM Conditioning Regimen in Patients With Diffuse Large B Cell Lymphoma Undergoing Autologous Transplantation.
    Cancer. 2020 Feb 12. doi: 10.1002/cncr.32752.
    PubMed     Abstract available

  11. DE FINE LICHT S, Maraldo MV, Specht L, Nielsen TT, et al
    Risk factors for cardiovascular disease in 5-year survivors of adolescent and young adult cancer: A Danish population-based cohort study.
    Cancer. 2020;126:659-669.
    PubMed     Abstract available

    January 2020
  12. CLOUGH L, Bayakly AR, Ward KC, Khan MK, et al
    Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32665.
    PubMed     Abstract available

    December 2019
  13. COHEN JB, Wei L, Maddocks KJ, Christian B, et al
    Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32640.
    PubMed     Abstract available

    November 2019
  14. SHAH UA, Shah N, Qiao B, Acuna-Villaorduna A, et al
    Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32556.
    PubMed     Abstract available

  15. GOYAL G, Tella SH, Funni S, Kommalapati A, et al
    Association between facility volume and mortality of patients with classic Hodgkin lymphoma.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32584.
    PubMed     Abstract available

    September 2019
  16. AYERS EC, Li S, Medeiros LJ, Bond DA, et al
    Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Cancer. 2019 Sep 30. doi: 10.1002/cncr.32526.
    PubMed     Abstract available

  17. BLOOMHARDT HM, Sint K, Ross WL, Rotatori J, et al
    Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health.
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32512.
    PubMed     Abstract available

  18. MAJOR A, Smith DE, Ghosh D, Rabinovitch R, et al
    Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
    Cancer. 2019 Sep 11. doi: 10.1002/cncr.32513.
    PubMed     Abstract available

  19. ABRAMSON JS, Irwin KE, Frigault MJ, Dietrich J, et al
    Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.
    Cancer. 2019 Sep 10. doi: 10.1002/cncr.32411.

    August 2019
  20. GANGARAJU R, Chen Y, Hageman L, Wu J, et al
    Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32488.
    PubMed     Abstract available

  21. EPPERLA N, Hamadani M, Reljic T, Kharfan-Dabaja MA, et al
    Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
    Cancer. 2019 Aug 23. doi: 10.1002/cncr.32464.
    PubMed     Abstract available

  22. FISET PO, Labbe C, Young K, Craddock KJ, et al
    Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
    Cancer. 2019 Aug 7. doi: 10.1002/cncr.32422.
    PubMed     Abstract available

    July 2019
  23. PAYNE JB, Dance KV, Farone M, Phan A, et al
    Patient and caregiver perceptions of lymphoma care and research opportunities: A qualitative study.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32401.
    PubMed     Abstract available

    Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32145.
    PubMed     Abstract available

    June 2019
  25. BLUM KA, Polley MY, Jung SH, Dockter TJ, et al
    Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Cancer. 2019 Jun 7. doi: 10.1002/cncr.32289.
    PubMed     Abstract available

  26. BHAKTA N
    Building the financial case for treating childhood cancer in resource-limited settings.
    Cancer. 2019;125:1774-1776.

  27. GODFREY JK, Nabhan C, Karrison T, Kline JP, et al
    Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Cancer. 2019;125:1830-1836.
    PubMed     Abstract available

    April 2019
  28. CHANDRASEKAR T, Goldberg H, Klaassen Z, Wallis CJD, et al
    The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity.
    Cancer. 2019;125:1050-1059.
    PubMed     Abstract available

    March 2019
  29. MOUNIER N, Anthony S, Busson R, Thieblemont C, et al
    Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
    Cancer. 2019 Mar 22. doi: 10.1002/cncr.32040.
    PubMed     Abstract available

  30. MRDENOVIC S, Zhang Y, Wang R, Yin L, et al
    Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32033.
    PubMed     Abstract available

  31. DENBURG AE, Laher N, Mutyaba I, McGoldrick S, et al
    The cost effectiveness of treating Burkitt lymphoma in Uganda.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32006.
    PubMed     Abstract available

    February 2019
  32. LOFSTEDT A, Ahlm C, Tesi B, Bergdahl IA, et al
    Haploinsufficiency of UNC13D increases the risk of lymphoma.
    Cancer. 2019 Feb 13. doi: 10.1002/cncr.32011.
    PubMed     Abstract available

  33. CAGLAYAN C, Goldstein JS, Ayer T, Rai A, et al
    A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31981.
    PubMed     Abstract available

    January 2019
  34. PARK SI, Horwitz SM, Foss FM, Pinter-Brown LC, et al
    The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31861.
    PubMed     Abstract available

  35. HAHN EE, Wu YL, Munoz-Plaza CE, Garcia Delgadillo J, et al
    Use of recommended posttreatment services for adolescent and young adult survivors of Hodgkin lymphoma.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31953.
    PubMed     Abstract available

  36. EYRE TA, Collins GP, Gupta A, Coupe N, et al
    A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
    Cancer. 2019;125:99-108.
    PubMed     Abstract available

    December 2018
  37. RIGTER LS, Spaander MCW, Aleman BMP, Bisseling TM, et al
    High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31903.
    PubMed     Abstract available

  38. HOLMQVIST AS, Chen Y, Berano Teh J, Sun C, et al
    Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group.
    Cancer. 2018 Dec 17. doi: 10.1002/cncr.31807.
    PubMed     Abstract available

  39. CALIP GS, Moran KM, Sweiss KI, Patel PR, et al
    Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Cancer. 2018 Dec 12. doi: 10.1002/cncr.31914.
    PubMed     Abstract available

  40. HESTER LL, Park SI, Wood WA, Sturmer T, et al
    Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31821.
    PubMed     Abstract available

  41. KANAGAL-SHAMANNA R, Jain P, Patel KP, Routbort M, et al
    Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer. 2018 Dec 3. doi: 10.1002/cncr.31831.
    PubMed     Abstract available

    October 2018
  42. BAZARBACHI A, Boumendil A, Finel H, Mohty M, et al
    Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Cancer. 2018 Oct 23. doi: 10.1002/cncr.31755.
    PubMed     Abstract available

  43. PARKER PA, Banerjee SC, Matasar MJ, Bylund CL, et al
    Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial.
    Cancer. 2018 Oct 18. doi: 10.1002/cncr.31767.
    PubMed     Abstract available

  44. KENZIK KM, Mehta A, Richman JS, Kilgore M, et al
    Congestive heart failure in older adults diagnosed with follicular lymphoma: a population-based study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31695.
    PubMed     Abstract available

    September 2018
  45. RIEDELL PA, Smith SM
    Double hit and double expressors in lymphoma: Definition and treatment.
    Cancer. 2018 Sep 25. doi: 10.1002/cncr.31646.
    PubMed     Abstract available

  46. HUNTINGTON SF, Hoag JR, Zhu W, Wang R, et al
    Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma.
    Cancer. 2018 Sep 14. doi: 10.1002/cncr.31688.
    PubMed     Abstract available

    June 2018
  47. SORIGUE M, Sancho JM
    The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma.
    Cancer. 2018 Jun 7. doi: 10.1002/cncr.31565.

  48. SUREDA A, Montoto S, Dreger P, Hamadani M, et al
    Reply to The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma.
    Cancer. 2018 Jun 7. doi: 10.1002/cncr.31564.

    May 2018
  49. KELLER FG, Castellino SM, Chen L, Pei Q, et al
    Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
    Cancer. 2018 May 8. doi: 10.1002/cncr.31519.
    PubMed     Abstract available

  50. ROMAGUERA JE, Wang M, Feng L, Fayad LE, et al
    Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31361.
    PubMed     Abstract available

    April 2018
  51. ARTS LPJ, Oerlemans S, Tick L, Koster A, et al
    More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry.
    Cancer. 2018 Apr 26. doi: 10.1002/cncr.31410.
    PubMed     Abstract available

  52. SMITH SM, Godfrey J, Ahn KW, DiGilio A, et al
    Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31374.
    PubMed     Abstract available

  53. LYNCH RC, Gopal AK
    Have we found the right patient population for transplantation in follicular lymphoma?
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31376.

  54. TOTA JE, Engels EA, Madeleine MM, Clarke CA, et al
    Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31359.
    PubMed     Abstract available

    March 2018
  55. GREENWELL IB, Staton AD, Lee MJ, Switchenko JM, et al
    Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31328.
    PubMed     Abstract available

    February 2018

  56. Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418.
    Cancer. 2018;124:867.

  57. SUREDA A, Zhang MJ, Dreger P, Carreras J, et al
    Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Cancer. 2018 Feb 9. doi: 10.1002/cncr.31264.
    PubMed     Abstract available

    December 2017
  58. PRINTZ C
    First person: Julie Vose, MD, MBA: The lymphoma specialist is focused on patients as well as organizational leadership.
    Cancer. 2017;123:4749.

    November 2017
  59. MYERS RM, Hill BT, Shaw BE, Kim S, et al
    Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31114.
    PubMed     Abstract available

  60. ARMENIAN SH, Mertens L, Slorach C, Venkataraman K, et al
    Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31110.
    PubMed     Abstract available

  61. AMMANN EM, Drake MT, Haraldsson B, Wallace RB, et al
    Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.
    Cancer. 2017;123:4168-4177.
    PubMed     Abstract available

  62. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Abstract available

    October 2017
  63. MAJZNER RG, Simon JS, Grosso JF, Martinez D, et al
    Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Cancer. 2017;123:3807-3815.
    PubMed     Abstract available

    September 2017
  64. HAN CH, Batchelor TT
    Diagnosis and management of primary central nervous system lymphoma.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.30965.
    PubMed     Abstract available

  65. EHRHARDT MJ, Mulrooney DA, Li C, Baassiri MJ, et al
    Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma.
    Cancer. 2017 Sep 15. doi: 10.1002/cncr.31019.
    PubMed     Abstract available

  66. HENDERSON TO, Parsons SK, Wroblewski KE, Chen L, et al
    Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30979.
    PubMed     Abstract available

    August 2017
  67. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Abstract available

    July 2017
  68. YANIK EL, Shiels MS, Smith JM, Clarke CA, et al
    Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States.
    Cancer. 2017 Jul 31. doi: 10.1002/cncr.30923.
    PubMed     Abstract available

  69. EPPERLA N, Maddocks KJ, Salhab M, Chavez JC, et al
    C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Cancer. 2017 Jul 27. doi: 10.1002/cncr.30895.
    PubMed     Abstract available

  70. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
    Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
    Cancer. 2017;123:2516-2523.
    PubMed     Abstract available

    June 2017
  71. HUI L, von Keudell G, Wang R, Zeidan AM, et al
    Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30818.
    PubMed     Abstract available

  72. CARBONE A, Gloghini A
    Hodgkin lymphoma classification: Are we at a crossroads?
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30824.

  73. PROVENCIO M, Royuela A, Torrente M, Pollan M, et al
    Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30795.
    PubMed     Abstract available

    May 2017
  74. RAJAGOPAL R, Miles GCP, Kotecha RS
    High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30768.

  75. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
    Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Cancer. 2017;123:1800-1809.
    PubMed     Abstract available

  76. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Abstract available

  77. GHAZAWI FM, Netchiporouk E, Rahme E, Tsang M, et al
    Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Cancer. 2017 May 10. doi: 10.1002/cncr.30758.
    PubMed     Abstract available

  78. KOFF JL, Flowers CR
    Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
    Cancer. 2017 May 2. doi: 10.1002/cncr.30740.

  79. HOWLADER N, Mariotto AB, Besson C, Suneja G, et al
    Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30739.
    PubMed     Abstract available

    April 2017
  80. VARGO JA, Patel A, Glaser SM, Balasubramani GK, et al
    The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.
    Cancer. 2017 Apr 5. doi: 10.1002/cncr.30697.
    PubMed     Abstract available

  81. DEFILIPP Z, Li S, El-Jawahri A, Armand P, et al
    High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30695.
    PubMed     Abstract available

    February 2017
  82. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
    A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
    PubMed     Abstract available

  83. First Person: Clara Bloomfield, MD.
    Cancer. 2017;123:369-370.

    January 2017
  84. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
    Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
    PubMed     Abstract available

    June 2016
  85. OLSZEWSKI AJ, Fallah J, Castillo JJ
    Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base.
    Cancer. 2016 Jun 23. doi: 10.1002/cncr.30112.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.